Literature DB >> 30132114

The pitfalls of per se thresholds in accurately identifying acute cannabis intoxication at autopsy.

Mary K Schwerdt1, James R Gill2.   

Abstract

Some laws in the United States define cannabis-impaired driving criteria using various per se language that uses specific concentrations of various cannabinoid compounds to establish driving-under-the-influence (DUI). We hypothesize that there will be decedents whose postmortem toxicology profiles would be considered indicative of an acute cannabinoid intoxication under varying DUI per se laws, despite having survived longer than the expected duration of cannabinoid impairment effects. This study examined decedents in whom quantified cannabis metabolites were detected in Connecticut medical examiner autopsy samples, in which the medically-confined survival interval was longer (4-12 and > 12 h) than the expected duration of cannabinoid impairment effects. Several of the 15 decedents, despite being intubated and/or comatose during the medically-confined period of abstinence, would have exceeded DUI per se limits based upon their toxicology results. The use of drug concentrations alone to equate to an acute cannabis intoxication may result in inappropriate arrest, prosecution, and civil liability.

Entities:  

Keywords:  Autopsy; Cannabinoids; Driving under the influence laws; Forensic pathology; Toxicology

Mesh:

Substances:

Year:  2018        PMID: 30132114     DOI: 10.1007/s12024-018-0019-2

Source DB:  PubMed          Journal:  Forensic Sci Med Pathol        ISSN: 1547-769X            Impact factor:   2.007


  25 in total

Review 1.  Risk of road accident associated with the use of drugs: a systematic review and meta-analysis of evidence from epidemiological studies.

Authors:  Rune Elvik
Journal:  Accid Anal Prev       Date:  2012-07-09

2.  Cannabinoid Dose and Label Accuracy in Edible Medical Cannabis Products.

Authors:  Ryan Vandrey; Jeffrey C Raber; Mark E Raber; Brad Douglass; Cameron Miller; Marcel O Bonn-Miller
Journal:  JAMA       Date:  2015 Jun 23-30       Impact factor: 56.272

3.  Postmortem redistribution of Δ9-tetrahydrocannabinol (THC), 11-hydroxy-THC (11-OH-THC), and 11-nor-9-carboxy-THC (THCCOOH).

Authors:  Michael G Holland; David M Schwope; Robert Stoppacher; Shane B Gillen; Marilyn A Huestis
Journal:  Forensic Sci Int       Date:  2011-07-20       Impact factor: 2.395

4.  The effect of orally and rectally administered delta 9-tetrahydrocannabinol on spasticity: a pilot study with 2 patients.

Authors:  R Brenneisen; A Egli; M A Elsohly; V Henn; Y Spiess
Journal:  Int J Clin Pharmacol Ther       Date:  1996-10       Impact factor: 1.366

5.  Cannabinoids in postmortem toxicology.

Authors:  Nikolas P Lemos; Eric A Ingle
Journal:  J Anal Toxicol       Date:  2011-09       Impact factor: 3.367

6.  Metabolic studies of delta-9-tetrahydrocannabinol in cancer patients.

Authors:  S Frytak; C G Moertel; J Rubin
Journal:  Cancer Treat Rep       Date:  1984-12

7.  Cannabinoid concentrations detected in fatal road traffic collision victims compared with a population of other postmortem cases.

Authors:  Rebecca Andrews; Kevin G Murphy; Limon Nahar; Sue Paterson
Journal:  Clin Chem       Date:  2015-08-03       Impact factor: 8.327

8.  Do Delta9-tetrahydrocannabinol concentrations indicate recent use in chronic cannabis users?

Authors:  Erin L Karschner; Eugene W Schwilke; Ross H Lowe; W David Darwin; Harrison G Pope; Ronald Herning; Jean L Cadet; Marilyn A Huestis
Journal:  Addiction       Date:  2009-10-05       Impact factor: 6.526

9.  Effect of Blood Collection Time on Measured Δ9-Tetrahydrocannabinol Concentrations: Implications for Driving Interpretation and Drug Policy.

Authors:  Rebecca L Hartman; Timothy L Brown; Gary Milavetz; Andrew Spurgin; David A Gorelick; Gary R Gaffney; Marilyn A Huestis
Journal:  Clin Chem       Date:  2016-02       Impact factor: 8.327

10.  Psychomotor function in chronic daily Cannabis smokers during sustained abstinence.

Authors:  Wendy M Bosker; Erin L Karschner; Dayong Lee; Robert S Goodwin; Jussi Hirvonen; Robert B Innis; Eef L Theunissen; Kim P C Kuypers; Marilyn A Huestis; Johannes G Ramaekers
Journal:  PLoS One       Date:  2013-01-02       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.